Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

868
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
868
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

868
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
868
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

245
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
245
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

359
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
359
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

542
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
542
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the concordance between ChatGPT-4 and EAU guidelines indications in bladder cancer management: a real-world study.

Minerva urology and nephrology·2026
Same author

Contemporary Practices in the Assessment and Management of Climacturia: Results from an International Survey.

European urology open science·2026
Same author

Performance of artificial intelligence chatbots compared with young academic urologists in reconstructive urology.

The French journal of urology·2026
Same author

Redefining clinical success in minimally invasive surgery for BPH: A composite endpoint integrating ejaculatory function, urinary improvement, and safety metrics.

Urologia·2026
Same author

Beyond surgery: the international masterclass in andrology and reconstructive surgery (iMARS) and the value of global collaboration in reconstructive urology and sexual medicine.

International journal of impotence research·2026
Same author

Urethral Complications After Masculinizing Genital Gender-affirming Surgery.

European urology focus·2026

Related Experiment Video

Updated: Jan 13, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

785

Association Between Isolated Postprandial Dyslipidemia And Erectile Dysfunction.

Celeste Manfredi1, Giampiero Della Rosa1, Simone Tammaro1

  • 1Department of Woman, Child and General and Specialized Surgery, Unit of Urology, University of Campania "Luigi Vanvitelli", Naples, Italy.

Andrology
|January 10, 2026
PubMed
Summary

Isolated postprandial dyslipidemia (IPD) is linked to increased prevalence and severity of erectile dysfunction (ED), similar to chronic dyslipidemia. Postprandial lipid testing can uncover metabolic risks affecting sexual health.

Keywords:
cardiometabolic riskerectile dysfunctionlipid profilepostprandial dyslipidemia

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.9K

Related Experiment Videos

Last Updated: Jan 13, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

785
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.9K

Area of Science:

  • Cardiovascular Health
  • Metabolic Syndrome
  • Sexual Medicine

Background:

  • Postprandial lipid testing is a recognized vascular health marker.
  • The link between postprandial dyslipidemia and erectile dysfunction (ED) is understudied.
  • Isolated postprandial dyslipidemia (IPD) may be missed by fasting tests despite atherogenic risks.

Purpose of the Study:

  • To investigate the association between IPD and erectile function.
  • To compare ED prevalence and severity in men with IPD, combined dyslipidemia (CD), and without dyslipidemia (WD).

Main Methods:

  • Cross-sectional study of 351 men aged ≥18 years.
  • Inclusion of same-day fasting and postprandial lipid testing and IIEF-EF questionnaire for erectile function.
  • Categorization into WD, IPD, and CD groups based on dyslipidemia criteria; multivariable logistic regression analysis.

Main Results:

  • ED prevalence was significantly higher in IPD (55.1%) and CD (57.0%) groups versus WD (32.8%).
  • Median IIEF-EF scores were lower in IPD and CD groups compared to WD, with statistically significant and clinically meaningful differences.
  • Adjusted analyses showed increased odds of ED in IPD and CD groups compared to WD; ED severity was also greater.

Conclusions:

  • IPD is associated with both the prevalence and severity of ED, similar to chronic dyslipidemia.
  • Postprandial lipid testing can identify metabolic risks relevant to sexual health.
  • Consideration of postprandial lipid testing in ED evaluations is recommended.